Hu H, Tan S, Xie M, Guo P, Yu Q, Xiao J
Front Pharmacol. 2023; 14:1167959.
PMID: 37705536
PMC: 10495838.
DOI: 10.3389/fphar.2023.1167959.
Wang T, Wei L, Lu Q, Shao Y, You S, Yin J
NPJ Precis Oncol. 2022; 6(1):84.
PMID: 36369474
PMC: 9652465.
DOI: 10.1038/s41698-022-00325-0.
Yin Q, Guo T, Zhou Y, Sun L, Meng M, Ma L
Thorac Cancer. 2021; 13(4):637-642.
PMID: 34964276
PMC: 8841708.
DOI: 10.1111/1759-7714.14291.
Fujita K, Naka M, Ito T, Kanai O, Maekawa K, Nakatani K
Respir Med Case Rep. 2021; 33:101393.
PMID: 33854939
PMC: 8024693.
DOI: 10.1016/j.rmcr.2021.101393.
Zhang R, Dong L, Yu J
Front Oncol. 2021; 10:544579.
PMID: 33520689
PMC: 7844084.
DOI: 10.3389/fonc.2020.544579.
Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.
Fan J, Wu J, Huang B, Zhu Y, Shi H, Dai X
Diagn Pathol. 2020; 15(1):42.
PMID: 32375829
PMC: 7201944.
DOI: 10.1186/s13000-020-00969-1.
Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country.
Andreis T, Correa B, Vianna F, de-Paris F, Siebert M, Leistner-Segal S
J Glob Oncol. 2019; 5:1-9.
PMID: 31532708
PMC: 6872182.
DOI: 10.1200/JGO.19.00174.
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y, Wang S, Zhang B, Qiao R, Xu J, Zhang L
Target Oncol. 2019; 14(2):169-178.
PMID: 30888598
DOI: 10.1007/s11523-019-00628-6.
Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib.
Purkayastha A, Kapoor A, Singh H, Sarin A, Sengupta P, Singh S
Lung India. 2018; 35(6):527-529.
PMID: 30381567
PMC: 6219139.
DOI: 10.4103/lungindia.lungindia_30_18.
[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].
Wang X, Zhong D
Zhongguo Fei Ai Za Zhi. 2018; 21(9):686-691.
PMID: 30201068
PMC: 6136996.
DOI: 10.3779/j.issn.1009-3419.2018.09.07.
Concomitant rearrangement and mutation in non-small cell lung cancer patients: a literature review of 100 cases.
Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M
Oncotarget. 2017; 8(35):59889-59900.
PMID: 28938691
PMC: 5601787.
DOI: 10.18632/oncotarget.17431.
CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.
Marino F, Accardo M, Franco R
J Thorac Dis. 2017; 9(7):1759-1762.
PMID: 28839956
PMC: 5542960.
DOI: 10.21037/jtd.2017.06.27.
Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant mutation and gene rearrangement: A case report and review of the literature.
Li Y, Su S, Cai G, Lin Q, Zhou Y, Ouyang J
Mol Clin Oncol. 2017; 7(2):173-182.
PMID: 28781781
PMC: 5532680.
DOI: 10.3892/mco.2017.1306.
Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E
Clin Transl Oncol. 2017; 20(2):140-149.
PMID: 28631135
DOI: 10.1007/s12094-017-1702-6.
[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy
in Non-small Cell Lung Cancer Patients in Shandong].
Qiao X, Ai D, Liang H, Mu D, Guo Q
Zhongguo Fei Ai Za Zhi. 2017; 20(1):14-20.
PMID: 28103968
PMC: 5973292.
DOI: 10.3779/j.issn.1009-3419.2017.01.02.
Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis.
Ye C, Wang J, Zheng S, Chai Y
Onco Targets Ther. 2016; 9:6605-6608.
PMID: 27822065
PMC: 5087704.
DOI: 10.2147/OTT.S121923.
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou N, Zhang X, Chen H, Zhou Q, Yan L, Xie Z
Oncotarget. 2016; 7(40):65185-65195.
PMID: 27533086
PMC: 5323147.
DOI: 10.18632/oncotarget.11218.
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.
Lee T, Lee B, Choi Y, Han J, Ahn M, Um S
J Pathol Transl Med. 2016; 50(3):197-203.
PMID: 27086595
PMC: 4876086.
DOI: 10.4132/jptm.2016.03.09.
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
Sweis R, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R
Cureus. 2016; 8(2):e513.
PMID: 27026837
PMC: 4807912.
DOI: 10.7759/cureus.513.
Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
Lee B, Lee T, Lee S, La Choi Y, Han J
Oncotarget. 2016; 7(17):23874-84.
PMID: 26992209
PMC: 5029670.
DOI: 10.18632/oncotarget.8074.
